Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Down 13.3% in September

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the target of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 5,200 shares, a decrease of 13.3% from the August 31st total of 6,000 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily volume of 30,200 shares, the short-interest ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Maxim Group upgraded Kiora Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, June 13th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Kiora Pharmaceuticals in a report on Thursday, August 22nd.

Institutional Trading of Kiora Pharmaceuticals

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC bought a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals makes up about 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 16th biggest holding. Stonepine Capital Management LLC owned about 6.86% of Kiora Pharmaceuticals at the end of the most recent reporting period. 76.97% of the stock is owned by institutional investors and hedge funds.

Kiora Pharmaceuticals Stock Performance

Shares of KPRX stock opened at $3.43 on Monday. The firm’s 50 day moving average is $3.78 and its 200 day moving average is $4.67. Kiora Pharmaceuticals has a 12 month low of $3.00 and a 12 month high of $8.98.

Kiora Pharmaceuticals (NASDAQ:KPRX) last posted its earnings results on Friday, August 9th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.42. The company had revenue of $0.02 million for the quarter. On average, equities research analysts predict that Kiora Pharmaceuticals will post 1.17 earnings per share for the current year.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.